

Deletion analysis of tumor and urinary DNA to detect bladder cancer: Urine supernatant versus urine sediment

TIBOR SZARVAS¹, ILONA KOVALSZKY¹, KATALIN BEDI¹, ATTILA SZENDROI², ATTILA MAJOROS², PÉTER RIESZ², TIBOR FÜLE¹, VIKTÓRIA LÁSZLÓ¹, ANDRÁS KISS³ and IMRE ROMICS²

¹First Department of Pathology and Experimental Cancer Research, Semmelweis University, H-1085 Budapest;

²Department of Urology, Semmelweis University, H-1091 Budapest; ³Second Department of Pathology, Semmelweis University, H-1082 Budapest, Hungary

Received January 10, 2007; Accepted March 30, 2007

Abstract. The accumulation of genetic alterations plays a role in the evolution of bladder cancer. These changes can be detected in the urine by DNA analysis of the cells exfoliated from the bladder wall enabling us to detect bladder cancer. The urine supernatant, besides the urine sediment, contains DNA, however in a much smaller amount. The origin of DNA in these two fractions is probably different. Our aim was to evaluate which fraction (supernatant or sediment) provides more reliable results in detecting tumors. We analyzed blood, urine and tumor samples taken from 80 individuals (44 patients with bladder cancer, 20 control patients and 16 healthy volunteers) by using 12 microsatellite markers mapped on 6 chromosomes. Microsatellite alterations were detected in the urine sediment and supernatant in 86% of the cancer cases. Urine sediment alone had a sensitivity of 68%, while urine supernatant alone indicated aberrations in 80% of the tumors. In the superficial (Ta/T1) cases, a considerable difference in sensitivity, 84 vs. 67%, was found between the two fractions in favor of urine supernatant. We also detected deletions in the control groups, although in a much lower proportion. Loss of the 16q24 chromosomal region showed a significant correlation with tumor stage ($p=0.02$). Microsatellite analysis of the urine is an efficient and noninvasive molecular method to detect bladder cancer. The analysis of free DNA in the urine supernatant provides a higher detection rate. The marker on the chromosomal region 16q24 is suggested to have a prognostic value.

Introduction

Multiple genetic changes are involved in the evolution and progression of human cancer (1,2). Besides oncogene activation, the inactivation of tumor suppressor genes is a key feature of tumorigenesis. Tumor suppressor genes may become inactive owing to several different mechanisms. The first hit is often deletion or recombination of a tumor suppressor gene, whereas the second hit can be hypermethylation of the promoter, point mutation or another deletion.

Microsatellites are short, polymorphic, tandem repeat segments dispersed throughout the human genome. Microsatellite markers are considered to be effective in detecting genetic alterations, such as microsatellite instability (MSI) and loss of heterozygosity (LOH) in human cancer (3,4).

Bladder cancer is the fourth most common malignant neoplasm in men and the eighth in women (5). The two main risks of these tumors are their high recurrence rate and progression depending on the initial tumor stage and grade (6). This emphasizes the importance of their early detection and a strict follow-up. Cystoscopy, as the 'gold standard' method, is invasive and uncomfortable. Urine cytology is a complementary diagnostic procedure. It does not provide, however, a reliable result in the case of papillary tumors since its sensitivity depends on the tumor grade (50%) (7,8).

Frequent LOH has been reported in bladder carcinoma on chromosomes 3, 4, 5, 8, 9, 11, 13, 17 and 18 involving the p53 and p16 tumor suppressor genes (9-13). Further studies demonstrated that mutated cancerous DNA is also detected in the corresponding urine sample (11,14). However, the presence of normal DNA derived from non-cancerous cells might interfere with the analysis. The ratio between the normal and cancerous epithelial cells in the urine sediment is probably related to tumor size. Therefore, analysis of the urine sediment provides a less sensitive result in noninvasive cases. On the other hand, the free DNA level in body fluids is elevated in cancer patients. The urine supernatant is suggested to contain free DNA that mainly originates from the tumor (15-19). This offers the possibility to enhance the sensitivity of microsatellite analysis by examining the free DNA isolated from the urine supernatant.

Correspondence to: Dr Tibor Szarvas, First Department of Pathology, Semmelweis University, H-1085 Budapest, Üllői út 26, Hungary
E-mail: sztibusz@t-online.hu
sztibusz@gmail.com

Key words: bladder cancer, microsatellite, loss of heterozygosity, deletion, fragment analysis, urine

Materials and methods

Patients. Matched blood, urine and tumor samples were collected from 44 patients (13 female, 31 male, and average age of 74 years) who underwent surgical resection of bladder cancer at the Department of Urology. The diagnosis was confirmed and tumors were graded after surgical resection by histological examination. The stages/grades were Ta in 7 cases, T1 in 18, T2 in 18, and T3 in one case. Tumor samples in 18 cases and urine sediment samples in 4 cases were not available for molecular analysis. Blood and urine samples were also collected from 20 control patients with non-malignant urinary diseases and 16 healthy individuals without any previous serious urological anamnesis. This study was approved by the Ethics Committee of the Semmelweis University.

Sample treatment. Tumor specimens obtained during surgery were immediately frozen. Blood and urine samples had been collected on the previous day. The urine was centrifuged at 3000 x g at 4°C for 5 min. The supernatant was separated, and the sediment was suspended in 0.5 ml 1X PBS. Samples were stored at -70°C before further processing.

DNA extraction. DNA was extracted from blood, tumor and the separated urine samples (described above) using Roche High Pure Template Isolation kit (Roche, Indianapolis, MN, USA) according to the manufacturer's protocol. Peripheral lymphocytes from each patient were used as the source of normal DNA.

Microsatellite analysis. Twelve fluorescently labeled primer pairs were used for microsatellite analysis: MBP, D9S162, IFNA, D16S476, D16S310, D18S51, D4S243, FGA, ACTBP, D9S171, D9S747, and MJD. Primer sequences were retrieved from the human genome database (<http://www.gdb.org>). PCR reactions were performed with 1 U of AmpliTaq Gold polymerase on 2 µl extracted DNA in a final volume of 25 µl as follows: one denaturation step at 95°C for 10 min, 35 cycles of denaturation at 95°C for 1 min, and annealing and extension at 60°C for 1 min. The 60°C annealing temperature is optimal for all primers (optimization data not shown). The PCR products were analyzed on a fluorescent DNA sequencer (ABI 310 genetic analyzer, Applied Biosystems, USA).

Urinary and tumor DNA were considered to show a deletion if an allele was reduced by >50%.

Optimization. In order to assess the standard deviation (SD) of the peak height ratios we performed parallel isolations (3x), PCR reactions (3x) and electrophoresis (3x). While we optimized the method we observed that when the relative fluorescence (RFU) did not reach 100, the SD of the peak height ratios increased, rendering these data unreliable. These cases were marked as 'amplification failure' and were excluded from the data evaluation.

Statistical analysis. The Cochran-Armitage trend test was performed to calculate which marker showed correlation with the pathological data.




Figure 1. LOHs on the 9q32 region.

Results

Microsatellite analysis was performed on blood, tumor and urine samples of 40 patients suffering from bladder cancer using 12 microsatellite markers. The average SD of the peak height ratios among parallel isolations of the 12 markers was very low (0.030, +0.084, and -0.008).

Twenty-two out of the 26 tumor specimens showed at least one LOH (85%). Detecting LOH in urine has a practical advantage since its sensitivity is of importance. At least one genetic alteration was found in the urine supernatant or sediment in 38 out of 44 urine samples (86%). The sensitivity of the supernatant alone was 80% (35/44), whereas that of the sediment was 68% (27/40) (Tables I and II).

The urine supernatant of the superficial (Ta/T1) tumors had a sensitivity of 84% (21/25), while that of the sediment was 67% (14/21). Urine samples taken from patients with muscle-invading tumors (T2/T3) had similar sensitivities; 74% (14/19) in the supernatant and 68% (13/19) in the sediment.

Regarding the 20 control patients with non-malignant urologic disease we detected LOHs in 4 patients (6 LOHs) (Tables I and II). One of them had urinary incontinence (LOH for 4 markers), another had cystitis (LOH for 1 marker) and 2 had BPH. Based on these data, the specificity of the method among patients with urological symptoms was evaluated as 80% (16/20).

Among the healthy controls we also found LOHs (2 in the urine sediment and 3 in the urine supernatant) in the urine samples of four individuals (Tables I and II). Therefore, the specificity of microsatellite analysis in this group was (13/16) 81% for the urine supernatant and 87.5% (14/16) for the urine sediment.

LOH was detected most frequently at the 9p21 (46%), 9q32 (34%) and 5q15 (34%) regions. The sensitivity reached 57% if 2 markers (9p21, 4q32) and 64% if 3 markers (9p21, 4q32 and 16q24) were used.

Table I. Summary of the raw data after microsatellite analysis.^a

		FGA	D4S243	ACTBP	D9S171	D9S162	IFNA	D9S747	MJD	MBP	D16S310	D16S476	D18S51						
		4q28	4q32	5q15	9p12	9p21	9p21	9q32	14q24	14q32	16q12	16q24	18q21						
Diagnosis		T	Uf	Us	T	Uf	Us	T	Uf	Us	T	Uf	Us	T	Uf	Us	T	Uf	Us
Bladder cancer	Superficial (Ta/T1)	719	TaG1																
	49	TaG2																	
	50	TaG2																	
	56	TaG2																	
	366	TaG2																	
	371	TaG2																	
	382	TaG2																	
	25	T1G1																	
	44	T1G3																	
	27	T1G1																	
	54	T1G1																	
	37	T1G2																	
	58	T1G2																	
	66	T1G2																	
	69	T1G2																	
	71	T1G2																	
	72	T1G2																	
	73	T1G2																	
	79	T1G2																	
	51	T1G3																	
	727	T1G2																	
	62	T1G3																	
	75	T1G3																	
710	T1G3																		
723	T1G3																		
Muscle invasive (T2/T3)	45	T2G2																	
	41	T2G2																	
	55	T2G2																	
	76	T2G2																	
	28	T2G3																	
	29	T2G3																	
	33	T2G3																	
	36	T2G3																	
	38	T2G3																	
	53	T2G3																	
	59	T2G3																	
	64	T2G3																	
	77	T2G3																	
	78	T2G3																	
84	T2G3																		
476	T2G3																		
720	T2G3																		
724	T2G3																		
63	T3G2																		
Control	Urological patients	1	Phimosi	Uf	Us	Uf	Us	Uf	Us	Uf	Us	Uf	Us	Uf	Us	Uf	Us	Uf	Us
		2	Stress inc.																
		7	Prostatitis																
		8	BPH																
		9	Colica renis																
		10	Kidney stone																
		11	Kidney stone																
		12	Cystitis																
		14	BPH																
		16	Kidney stone																
		17	BPH																
		18	Colica renis																
		19	BPH																
21	BPH																		
22	Kidney stone																		
24	Cystitis																		
27	Cystitis																		
28	BPH																		
29	Kidney stone																		
31	Kidney stone																		
Healthy individuals	5																		
	23																		
	381																		
	578																		
	748																		
	876																		
	979																		
	109																		
	367																		
	238																		
	922																		
	623																		
	382																		
192																			
129																			
109																			

^aMicrosatellite analysis of tumor (T), urine sediment (Us), and urine supernatant (Uf). LOHs are shown in red boxes. Blue boxes indicate the homozygous (not informative) cases, the gray boxes indicate missing samples and the yellow boxes represent 'amplification failures'. Stage and grade are shown in the first column. The analyzed chromosomal regions are in the first row.

Table II. Specificity and sensitivity of the microsatellite analysis.

	Bladder cancer patients			Control patients (n=20)	Healthy control patients (n=16)
	Superficial (n=25)	Muscle invasive (n=19)	Σ (n=44)		
LOH in at least one sample	23/25 92%	18/19 95%	41/44 93%	4/20 20%	5/16 31%
A minimum of one LOH in the urine supernatant	21/25 84%	14/19 74%	35/44 80%	4/20 20%	3/16 19%
A minimum of one LOH in the urine sediment	14/21 67%	13/19 68%	27/40 68%	1/20 5%	2/16 12.5%

Discussion

The accumulation of genetic alterations including deletions is one of the main features of tumors. In accordance with other groups, we concluded that the assessment of genetic loss by microsatellite analysis offers a sensitive tool for detecting bladder cancer (11,20). The successful detection of genetic errors in the urine bears great importance in the diagnosis and follow-up of patients with bladder carcinoma (21).

The contamination with normal DNA is a major concern of microsatellite analysis. In the presence of contaminating normal DNA, both alleles, even the one deleted in the tumor, become amplified during PCR. As this can mask the LOH present in tumor cells, it reduces the sensitivity of detection. The proportion of DNA originating from normal cells versus tumor cells in the urine sediment cannot be assessed in advance; it is likely to depend on the tumor size and/or the amount of inflammatory cells in the urine. On the other hand, increased amounts of *cell-free* DNA were observed in the plasma/serum of cancer patients (15-19). These amounts are proportional to tumor burden, and in at least some cancer patients nearly the whole free DNA content of the plasma is derived from tumor cells (22,23). Elevated cell-free DNA levels were found, not only in the plasma, but also in other body fluids such as pleural fluid and urine, in cancer patients (17,24). Zancan and colleagues were able to detect bladder cancer in all of the cases when the urinary cell-free DNA concentration was >250 ng/ml (17). However, the origin of this DNA fraction has not been fully clarified. Jahr and coworkers demonstrated the apoptotic and necrotic origin of free DNA in the serum and concluded that it principally was derived from the expanding tumor tissue (25).

Our objective was to examine whether the sensitivity of microsatellite analysis could be improved by separating urine sediment from the supernatant, assuming that the free DNA in the supernatant originates mainly from the disintegrated cells of the tumor.

The overall sensitivity of the method in urine samples (supernatants and sediments) was 86%. The detection rate was the highest in the superficial (Ta/T1) cases (23/25, 92%), while it was lower in the muscle invasive (T2/T3) ones (15/19, 79%) (Tables I and II). Sensitivity was 68% in the

urine sediment, and 80% in the supernatant. These results confirm that the use of the urine supernatant enhances the sensitivity of microsatellite analysis.

Sixty-seven percent of the genetic alterations found in the tumors were identified in the corresponding urine supernatant. Notably, we also detected alterations that were not present in the examined tumor specimen. These alterations may have originated from other tumor clone(s) also present in the tumor but not in the examined specimen.

In the literature, specificity is almost exclusively determined by using samples from healthy people, thus a sensitivity of 100% is reported (26-29). On the other hand, it might be interesting to observe how other urologic diseases affect sensitivity. Two studies dealing with this problem have provided conflicting results. In one study of BPH and cystitis it was found that inflammation can also cause genetic alterations, thus deteriorating the sensitivity of tumor detection (19). In the other study, no loss of heterozygosity was found in the control group including five patients with cystitis (20).

Out of 20 control patients with other urological problems, 4 exhibited loss of heterozygosity (Table II). One of these patients was treated for urinary stress incontinence, another with cystitis, whereas in the other two individuals BPH was diagnosed. Based on these data, the specificity of the method in this group in respect to urine supernatant and urine sediment was evaluated as 80%. However, these data have to be considered critically since we were unable to track the control patients having 4 LOHs in the urine sample. Therefore we could not exclude the presence of bladder cancer.

We found LOHs in 3 out of the 16 healthy control patient samples; 2 in the urine sediment and 3 in the urine supernatant (Tables I and II). Hence, the evaluated specificity in this group was 81% in the case of the urine supernatant and 87.5% in the case of the urine sediment. However, the low DNA content (1) of the urine supernatant was a general attribute of these specimens. This can influence the amplification by either causing 'amplification failure' or alteration of allelic ratio. We performed parallel reproducibility experiments and found that the SDs of the peak height ratios increase strongly if the relative fluorescence (RFU)

fails to reach 100. In order to avoid this problem we excluded these unreliable results (RFU<100) from the analysis.

Notably the distribution of poor amplifications (RFU<100) from the urine supernatant was variable among the three groups. In the tumor patients the failure rate was 15%, in the urological control group it was 27%, and in the healthy individuals it was 48%, in contrast with the urine sediment where similar failure rates were found in all three groups (4, 3, and 0%). This further supports the formerly cited theory that the DNA content of urine supernatant, but not of the sediment, is elevated in the presence of a tumor.

The most effective marker was the IFNA in the 9p21 chromosomal region which showed LOH in 46% of the cases and 57% if combined with D4S243 (4q32). The use of D16S476 (16q24) as a third marker increased the sensitivity to 64%.

The loss of the chromosomal region 16q24 showed a strong correlation with tumor stage (p=0.02) but not with grade (p=0.11). This marker may have a prognostic value.

Acknowledgements

We are grateful for the financial assistance of the National Research and Development Program (project no. NKFP-1a/0023/2002) and the National Office for Research and Technology (project no. OMF-606/2003).

References

1. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. *Cell* 61: 759-767, 1990.
2. Lengauer C, Kinzler KW and Vogelstein B: Genetic instabilities in human cancers. *Nature* 396: 643-649, 1998.
3. Mao L, Lee DJ, Tockman MS, Erozan YS, Askin F and Sidransky D: Microsatellite alterations as clonal markers for the detection of human cancer. *Proc Natl Acad Sci USA* 91: 9871-9875, 1994.
4. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, Murphree AL and Strong LC: Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. *Nature* 305: 779-784, 1983.
5. Cohen SM and Johansson SL: Epidemiology and etiology of bladder cancer. *Urol Clin N Am* 19: 421-428, 1992.
6. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD and Hawkins IR: Superficial bladder cancer: progression and recurrence. *J Urol* 130: 1083-1086, 1983.
7. Farrow GM, Utz DC and Rife CC: Morphological and clinical observations of patients with early bladder cancer treated with total cystectomy. *Cancer Res* 36: 2495-2501, 1976.
8. Lewis RW, Jackson AC, Murphy WM, Leblanc GA and Meehan WL: Cytology in the diagnosis and follow-up of transitional cell carcinoma of the urothelium: Review with a case series. *J Urol* 116: 43-46, 1976.
9. Saran KK, Gould D, Godec CJ and Verma RS: Genetics of bladder cancer. *J Mol Med* 74: 441-445, 1996.
10. Orntoft TF and Wolf H: Molecular alterations in bladder cancer. *Urol Res* 26: 223-233, 1998.
11. Mao L, Schoenberg M, Scicchitano M, Erozan YS, Merlo A, Schwab D and Sidransky D: Molecular detection of primary bladder cancer by microsatellite analysis. *Science* 271: 659-662, 1996.
12. Bartoletti R, Dal Canto M, Cai T, Piazzini M, Travaglini F, Gavazzi A and Rizzo M: Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment. *Oncol Rep* 13: 531-537, 2005.
13. Keen AJ and Knowles MA: Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. *Oncogene* 9: 2083-2088, 1994.
14. Utting M, Werner W, Dahse R, Schubert J and Junker K: Microsatellite analysis of free tumor DNA in urine, serum and plasma of patients: a minimally invasive method for the detection of bladder cancer. *Clin Cancer Res* 8: 35-40, 2002.
15. Shapiro B, Chakrabarty M, Chon EM and Leon SA: Determination of circulating DNA levels in patients with benign or malignant tumors. *Cancer* 51: 2116-2120, 1983.
16. Schmidt B, Engel E, Carstensen T, Weickmann S, John M, Witt C and Fleischhacker M: Quantification of free RNA in serum and bronchial lavage: a new diagnostic tool in lung cancer detection? *Lung Cancer* 48: 145-147, 2005. E-pub Dec 16, 2004.
17. Zancan M, Franceschini R, Mimmo C, Vianello M, Di Tonno F, Mazzariol C, Malossini G and Gion M: Free DNA in urine: a new marker for bladder cancer? Preliminary data. *Int J Biol Markers* 20: 134-136, 2005.
18. Taback B and Hoon DS: Circulating nucleic acids in plasma and serum: past, present and future (Review). *Curr Opin Mol Ther* 6: 273-278, 2004.
19. Anker P, Mulcahy H, Chen XQ and Stroun M: Detection of circulating tumor DNA in the blood (plasma/serum) of cancer patients. *Cancer Metastasis Rev* 18: 65-73, 1999.
20. Mourah S, Cussenot O, Vimont V, Desgrandchamps F, Teillac P, Cochant-Priollet B, Le Duc A, Fiet J and Soliman H: Assessment of microsatellite instability in urine in the detection of transitional-cell carcinoma of the bladder. *Int J Cancer* 79: 629-633, 1998.
21. Amira N, Mourah S, Rozet F, Teillac P, Fiet J, Aubin P, Cortesse A, Desgrandchamps F, Le Duc A, Cussenot O and Soliman H: Non-invasive molecular detection of bladder cancer recurrence. *Int J Cancer* 101: 293-297, 2002.
22. Goessl C, Heicappell R, Munker R, Anker P, Stroun M, Krause H, Muller M and Miller K: Microsatellite analysis of plasma DNA from patients with clear cell renal carcinoma. *Cancer Res* 58: 4728-4732, 1998.
23. Nawroz H, Koch W, Anker P, Stroun M and Sidransky D: Microsatellite alterations in serum DNA of head and neck cancer patients. *Nat Med* 2: 1035-1037, 1996.
24. Chan MH, Chow KM, Chan AT, Leung CB, Chan LY, Chow KC, Lam CW and Lo YM: Quantitative analysis of pleural fluid cell-free DNA as a tool for the classification of pleural effusions. *Clin Chem* 49: 740-745, 2003.
25. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayr FO, Hesch RD and Knippers R: DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. *Cancer Res* 61: 1659-1665, 2001.
26. Eissa S, Kassim S and El-Ahmady O: Detection of bladder tumors: role of cytology, morphology-based assays, biochemical and molecular markers. *Curr Opin Obstet Gynecol* 15: 395-403, 2003.
27. von Knobloch R, Hegele A, Brandt H, Olbert P, Heidenreich A and Hofmann R: Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis. *Int J Cancer* 94: 67-72, 2001.
28. Christensen M, Wolf H and Orntoft TF: Microsatellite alterations in urinary sediments from patients with cystitis and bladder cancer. *Int J Cancer* 85: 614-617, 2000.
29. Little B, Hughes A, Young MR and O'Brien A: Use of polymerase chain reaction analysis of urinary DNA to detect bladder carcinoma. *Urol Oncol* 23: 102-107, 2005.